FOXO4-DRI

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

• Active malignancy or history of cancer: FOXO4-DRI disrupts the FOXO4-p53 survival interaction that senescent cells depend on; however, many cancer cells also exploit FOXO4-mediated p53 sequestration as a pro-survival mechanism; in the oncological context, uncontrolled p53 nuclear re-entry in tumor cells without clinical supervision could produce unpredictable outcomes; use in active cancer subjects requires oncological evaluation. Limited / unverified
• Pregnancy: the pro-apoptotic cellular clearance mechanism of FOXO4-DRI has not been evaluated in the context of pregnancy; placental trophoblast cells and fetal cells share some characteristics with senescent cells and the developmental safety profile is entirely uncharacterized. Limited / unverified
• Active systemic immunosuppression (organ transplant recipients, high-dose corticosteroid therapy, chemotherapy-induced immunosuppression): the clearance of senescent cells generates a transient acute inflammatory response as cleared cell debris is processed by the immune system; in immunosuppressed subjects this response may be dysregulated. Limited / unverified
• Severe autoimmune disease in active flare: the acute inflammatory pulse from senescent cell clearance could worsen an already hyperactivated autoimmune inflammatory state. Limited / unverified
• Severe hepatic or renal impairment: the cellular clearance and metabolic demands of FOXO4-DRI-induced apoptosis place additional burden on hepatic and renal clearance pathways; safety in severe organ impairment is uncharacterized. Limited / unverified
• Known hypersensitivity to FOXO4-DRI, D-amino acid retro-inverso peptides, or formulation excipients. Limited / unverified
• Subjects under age 25: the cellular senescence burden in young subjects is negligible; senolytic activity in tissue with a low senescent cell fraction has no meaningful therapeutic target and could theoretically disrupt progenitor cell populations that express stress-related FOXO4 activity transiently. Limited / unverified
• Concurrent use of other senolytics (dasatinib, quercetin, navitoclax): additive senolytic activity may produce excessive simultaneous senescent cell clearance, overwhelming the immune system's capacity to process cleared debris and producing severe SASP-related inflammatory responses. Limited / unverified

Side effects (limited evidence)

• Lethargy and fatigue during cellular clearance: the most consistently reported adverse effect; as large numbers of senescent cells undergo apoptosis, the immune system mobilizes to clear the cellular debris; the metabolic demand and the transient SASP cytokine release during clearance produce a flu-like fatigue state; duration correlates with the senescent cell burden being cleared. Limited / unverified
• Joint aches and musculoskeletal discomfort: senescent cells are disproportionately abundant in joint-adjacent tissues (cartilage, synovium, periarticular fat); their clearance produces a transient local inflammatory response characterized by joint stiffness and aching; typically self-limiting as inflammation resolves post-clearance. Limited / unverified
• Transient acute inflammatory pulse: as senescent cells die and SASP factors are abruptly released from clearing cells, serum inflammatory markers (CRP, IL-6) transiently elevate before falling to below-baseline levels as the senescent cell burden decreases; the net long-term effect is anti-inflammatory but the acute clearance phase may be transiently pro-inflammatory. Limited / unverified
• Mild headache: uncommon; possibly related to the systemic inflammatory response during cellular clearance. Limited / unverified
• Injection site reactions: mild redness and soreness at the subcutaneous administration site; standard for peptide injection. Limited / unverified
• Transient liver enzyme elevation: liver contains a high density of senescent hepatic stellate cells and hepatocytes; FOXO4-DRI-driven clearance in liver tissue may transiently elevate ALT/AST as hepatocyte turnover occurs; typically resolves within 2-4 weeks. Limited / unverified
• Skin changes: some subjects report changes in skin texture, tone, or mild hair regrowth consistent with the de Keizer mouse data showing fur regrowth; these are the desired senolytic tissue restoration effects rather than adverse events. Limited / unverified
• Unknown long-term safety profile: the human clinical evidence base for FOXO4-DRI is entirely preclinical; the full long-term safety spectrum in humans is not established; all use is strictly research-context with this caveat acknowledged. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding